Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2011, Article ID 195831, 6 pages
http://dx.doi.org/10.1155/2011/195831
Research Article

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab

1Department of Biometrics, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA
2Neurology Clinical Development, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA
3Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA

Received 2 May 2011; Revised 17 November 2011; Accepted 19 November 2011

Academic Editor: Mamede de Carvalho

Copyright © 2011 Y. C. Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Y. C. Wang, A. Sandrock, J. R. Richert, L. Meyerson, and X. Miao, “Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab,” Neurology Research International, vol. 2011, Article ID 195831, 6 pages, 2011. https://doi.org/10.1155/2011/195831.